We Had Seven Days of Cash Left with Dan Rose
In this episode of the Crux of Cardio, Jordan Burgin sits down with Dan Rose, CEO of Endovascular Engineering (E2), to talk about building, exiting, and doing it all over again this time in one of the hottest spaces in cardiovascular medicine.
Dan joined LimFlow as its first employee, guided it through an FDA approval, a landmark New England Journal of Medicine publication, and ultimately its acquisition by Inari Medical. Weeks before that deal closed, E2 had seven days of cash in the bank.
Key Topics
The PE thrombectomy market and what the Stryker–Inari and Boston Scientific–Penumbra…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.